Officials in Canada said on 25 February 2021 that Canada's COVID-19 vaccination campaign is ramping up after earlier supply disruptions, Reuters news agency reported on Friday.
Canada's deputy chief public health officer, Howard Njoo, was quoted as telling a briefing that over 240,000 COVID-19 doses were injected last week, the most in more than a month.
"We are seeing positive signs that the rollout is ramping up. ... This is a reflection of greater supply," he said, adding that about 2.9% of Canadians had received at least one dose and this percentage is expected to significantly increase throughout March 2021.
Major General Dany Fortin, in charge of coordinating the COVID-19 vaccine rollout, has said a total of 643,000 doses had been distributed this week, the highest amount yet.
Reportedly, Canada has deals with US pharmaceutical companies Pfizer Inc and Moderna Inc to purchase COVID-19 vaccines, but both companies ran into production problems last month and reduced shipments.
Canada says it is still on track to receive a total of six million doses from Pfizer and Moderna by the end of March 2021 and that anyone who wants a shot can get one by the end of September 2021.
So far, Canada has recorded a total of 21,807 COVID-19 deaths and 855,126 cases.
AstraZeneca launches online platform to expand patient access to medications
Sanofi increases Sanofi Ventures funding by USD625m to boost biotech and digital health investments
GC Biopharma submits IND application in South Korea for Phase 1 trial of COVID-19 vaccine candidate
AusperBio completes patient enrolment in two Phase II clinical trials of AHB-137
LakeShore Biopharma receives Nasdaq delisting determination letter
Valneva reports strong Phase 2 booster results for Lyme disease vaccine candidate VLA15
GC Biopharma files IND for Phase 3 trial of BARYCELA in Thailand
Novavax COVID-19 vaccine approved in US
WHO and UNICEF deploy PharmaJet's Tropis ID system in Afghanistan polio campaign
FDA grants priority review for GSK's gepotidacin gonorrhoea indication
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement